Sinopharm Modern released its 2026 interim report. Total operating revenue was 3.94 billion yuan, down 19.22% year-on-year, and net profit attributable to the parent was 276 million yuan, down 58.99% year-on-year. Net cash inflow from operating activities was 48.2779 million yuan, a sharp decline of 92.77% year-on-year. The company's asset-liability ratio was 17.76%, gross margin was 29.60%, and ROE was 2.00%, all lower than the same period last year. Diluted earnings per share were 0.21 yuan, a decrease of 0.30 yuan year-on-year. The number of shareholders was 35,800, and the top ten shareholders held 63.24% of the total share capital.
Shanghai Shyndec Pharmaceutical Co LtdNet profit down 58.99% and revenue down 19.22% in interim report.